ANI Pharma gets US FDA nod for Nitrofurantoin Oral Suspension USP

hanuman

Active member
US-FDA-1.jpg


ANI Pharmaceuticals has received US Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Nitrofurantoin Oral Suspension USP, 25 mg/5 ml.


ANI’s Nitrofurantoin Oral Suspension is the generic version of the Reference Listed Drug (RLD) Furadantin Oral Suspension 25 mg/5 ml. The current annual US market for Nitrofurantoin Oral Suspension is approximately $55.5 million, according to the latest estimates by IQVIA/IMS Health.


“New product approvals and launches remain our top priority as we continue to grow our generics business. The FDA approval and commercialisation of Nitrofurantoin Oral Suspension is another example of how we are continuing to bring limited-competition products to market, with the goal of serving the patient populations that can benefit,” stated Nikhil Lalwani, President and CEO, ANI.





The post appeared first on .
 
Top
AdBlock Detected

We get it, advertisements are annoying!

Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.

I've Disabled AdBlock